Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal

Posted inBiotechnology

Dimerix has bought an acute kidney injury drug from Mission Therapeutics, paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready asset.